Investigators: Biosimilar Pegfilgrastim Has Advantages Over Wearable Injector

December 1, 2020

Tony Hagen


The wearable injector has a failure rate that adds hospitalization costs; therefore, biosimilar pegfilgrastim may hold cost advantages, investigators conclude.

Poll: How Much Do You Know About Biosimilar Suffixes?

November 30, 2020


Biosimilar suffixes were intended to help with pharmacovigilance, but they are not widely understood.

Providers Exploit Minor Differences Between Innovator Drugs and Biosimilars

November 24, 2020

Skylar Jeremias


Minute differences between biosimilars and reference products are not considered “clinically meaningful,” but these differences are exploitable when it comes to addressing allergies related to originator products.

European Commission Approves Pfizer's Pegfilgrastim Biosimilar

November 23, 2020

Tony Hagen


Pfizer aims to begin marketing Nyvepria in the European Union in the first quarter of 2021.

Opinion: Embrace the Era of Next-Generation Biologics

November 21, 2020

Bincy P. Abraham, MD


Bincy P. Abraham, MD, explains that even when payers allow coverage for biosimilars, providers may still be hesitant to use them.

Not So Different: Kathy Oubre on the Benefits of Using Biosimilars in a Community Oncology Practice

November 15, 2020


Kathy Oubre, MS, chief operating officer at the Pontchartrain Cancer Center in Louisiana, discusses the value of biosimilars.

ACR: UHC's New Co-pay Policy Is "Disastrous" for Patients

October 29, 2020

Tony Hagen


The American College of Rheumatology (ACR) has joined with other provider groups in opposing a UnitedHealthcare (UHC) plan that could increase patient out-of-pocket costs.

Safety, Efficacy, and Savings Result From Study of Nonmedical Switching

October 26, 2020

Tony Hagen


A study of mandatory switching for patients with rheumatologic conditions led to savings without effect on safety or efficacy.

Europeans Devise Checklist for Promoting Biosimilar Use

October 24, 2020

Deana Ferreri, PhD


European investigators have derived a set of core principals for developing higher utilization of biosimilars.

Need for Biosimilar Cooperation Among Hospitals, Infusion Centers, and Payers Is Identified

October 22, 2020

Skylar Jeremias


Overcoming biosimilar uptake barriers will take collaboration and policy change by hospitals, infusion clinics, and health plans, presenters said at the Academy of Managed Care Pharmacy Nexus 2020 Virtual conference.